Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday, March 21st.
According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. “
LXRX has been the topic of several other reports. BidaskClub upgraded shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. ValuEngine lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Needham & Company LLC lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd. Wedbush reiterated an “outperform” rating and set a $38.00 price target on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Finally, JPMorgan Chase lowered shares of Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and cut their price target for the stock from $15.00 to $10.00 in a research note on Wednesday, February 14th. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Lexicon Pharmaceuticals has an average rating of “Hold” and a consensus target price of $24.50.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 142.86% and a negative return on equity of 143.31%. The firm had revenue of $33.05 million for the quarter, compared to analyst estimates of $29.84 million. During the same period last year, the business earned ($0.31) EPS. Lexicon Pharmaceuticals’s revenue for the quarter was up 43.7% compared to the same quarter last year. analysts predict that Lexicon Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Jump Trading LLC purchased a new position in Lexicon Pharmaceuticals during the 4th quarter worth $104,000. Two Sigma Advisers LP purchased a new position in Lexicon Pharmaceuticals during the 4th quarter worth $104,000. Parametric Portfolio Associates LLC purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter worth $182,000. Quantitative Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals during the 4th quarter worth $117,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Lexicon Pharmaceuticals during the 3rd quarter worth $149,000.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.